Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial

BACKGROUND: This phase II proof-of-concept study assessed the efficacy and safety of BI 425809, a novel selective glycine transporter-1 inhibitor, for the treatment of cognitive impairment associated with probable Alzheimer’s disease dementia. METHODS: This 12-week, multicenter, double-blind, placeb...

Descripción completa

Detalles Bibliográficos
Autores principales: Wunderlich, Glen, Blahova, Zuzana, Garcia, Miguel, Jessen, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883916/
https://www.ncbi.nlm.nih.gov/pubmed/36709275
http://dx.doi.org/10.1186/s13195-023-01163-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883916/
https://www.ncbi.nlm.nih.gov/pubmed/36709275
http://dx.doi.org/10.1186/s13195-023-01163-3

Ejemplares similares